All In Biotech

NDA 219843 · Rosemont Pharms

Atmeksi

Methocarbamol · Oral · Muscle Relaxant

Last checked: Nov 20, 2026Latest source record: Jul 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Jul 30, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

33

8 Phase 3, 2 recruiting

FAERS reports

17,199

10,693 serious, 1,418 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 13, 2026.

ATMEKSI (methocarbamol) oral suspension is a muscle relaxant indicated as: an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions in patients 16 and older. 1.1 Acute, painful musculoskeletal conditions. ATMEKSI is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions in patients 16 and older. 1.1 Acute, painful musculoskeletal conditions. ATMEKSI is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions in patients 16 and older.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ATMEKSI · METHOCARBAMOL 750MG/5ML · SUSPENSION, ORAL · Prescription
  • ATMEKSI · METHOCARBAMOL 750MG(5ML) · SUSPENSION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Methocarbamol" as an intervention, any sponsor and status, largest first.

All 33 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue1,273
  • pain1,245
  • nausea1,191
  • drug ineffective1,140
  • headache973
  • diarrhoea882
  • off label use837
  • fall813
  • dyspnoea788
  • arthralgia766
  • dizziness696
  • back pain652

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004108
2005134
2006131
200784
2008134
2009176
2010199
2011253
2012349
2013346
2014378
2015695
2016972
2017845
20181,084
20191,240
20201,353
20211,120
20221,214
20231,273
20241,485
20251,975
20261,651

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 30 on PubMed

Sponsor: Rosemont Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.